Clinical trials: Human Papillomavirus
Health Personnel Attitude, Health Knowledge, Attitudes, Practice
Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention
Healthcare providers (HCP) serving the El Paso U.S.-Mexico Border Region will be recruited to compare educational and professional skills interventions focused on the human papillomavirus (HPV).
- Trial name
- NCT05120869
- Testing
- Tailored HPV Education and Professional Skills Intervention Group, General HPV Education and Communication Skills Control Group
- Where
- 2 sites in United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
This study is designed to evaluate the immunogenicity, safety, and tolerability of Gardasil® (quadrivalent human papillomavirus [qHPV] vaccine, V501) in Chinese girls aged 9-19 years and young women aged 20-26 years.
- Trial name
- NCT03493542
- Testing
- V501
- Where
- China
- Volunteers
- 766 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Anogenital Human Papilloma Virus Infection
3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China
The thirty-six-month immunogenicity evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese female subjects aged 9 to 45 years and male subjects aged 9 to 15 years.
- Trial name
- NCT01427777
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Guangxi Center for Disease Control and Prevention
Infections, Papillomavirus
Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study
This phase IIIb study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in the HPV-023 (NCT00518336) study and received a placebo in the HPV-001 (NCT00689741)…
- Trial name
- NCT01418937
- Testing
- CervarixTM (GSK580299)
- Where
- 5 sites in Brazil
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Completion of Three Dose Series of HPV, Improvement in Vaccine Intervals Between HPV Doses
The Efficacy of Reminders to Complete HPV Series
The human papillomavirus (HPV) vaccine is routinely recommended for both adolescent girls and boys starting at age 11, although it can be offered as young as 9 years of age.
- Trial name
- ICHAT (NCT01731496)
- Testing
- Telephone reminder, Text Message reminder
- Where
- 3 sites in United States
- Volunteers
- 749 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Human Papillomavirus Vaccines, Influenza Vaccines
Attitudes Toward Human Papillomavirus and Influenza Vaccination Among Mothers of Early Adolescents
The purpose of this study was to determine whether messages about 1. relative risk of vaccination vs. other activities and 2. strength of doctor's recommendation influenced parental intention to get own child vaccinated against…
- Conditions
- Human Papillomavirus Vaccines, Influenza Vaccines, Attitude to Health
- Trial name
- NCT02358083
- Testing
- Provider Communication about Vaccination
- Volunteers
- 1,165 people, healthy volunteers welcome
- Sponsor
- Indiana University
Papillomavirus Infections
Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM)
The purpose of this study is to determine rates of oral and genital human papillomavirus (HPV) infections, and look at risk factors for HPV infection in healthy mid-adult women.
- Trial name
- WHIM (NCT01295242)
- Where
- United States
- Volunteers
- 409 people, healthy volunteers welcome
- Sponsor
- University of Washington
Anogenital Dysplasia
Ano-genital Human Papillomavirus (HPV) Infection, Precancerous Lesions and Genital Warts Among Danish Renal Transplant Recipients
Transplant-related malignancies have emerged as one of the important complications after organ transplantation. Some studies have shown that transplant recipients have an increased risk of developing cancer, especially…
- Trial name
- NCT03018327
- Where
- Denmark
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Human Papillomavirus, Infection
Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)
PROJECT JUSTIFICATION: Cervical cancer is a serious public health problem in Brazil, and is the cause of significant morbidity and mortality among Brazilian women.
- Trial name
- NCT01159834
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- Barretos Cancer Hospital
Anal High Grade Squamous Intraepithelial Lesion
Safety of Anal Curcumin
The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current…
- Trial name
- NCT06626230
- Testing
- Curcuminoid Capsules
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Lisa Flowers
Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine
The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) （HPV）and Measles Mumps and Rubella Combined Vaccine, Live（MMR）
- Conditions
- Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Measles, Rubella
- Trial name
- NCT05279248
- Testing
- HPV+MMR（0d），HPV（6m）, HPV（0d），HPV（6m），MMR（7m）, MMR（0d），HPV（1m），HPV（7m）
- Where
- 2 sites in China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Human Papillomavirus (HPV), Awareness and Knowledge Level
Effect of HPV Education on Women's Knowledge
This interventional study aims to evaluate the effectiveness of an educational program on women's knowledge of Human Papillomavirus (HPV), HPV vaccination, and screening.
- Trial name
- NCT07231263
- Testing
- HPV Awareness Education Group
- Where
- Turkey (Türkiye)
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
Infections, Papillomavirus
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
The purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases (AIDs) following females who have received at the least the first dose of Cervarix® as part of their routine health care.
- Trial name
- NCT01153906
- Testing
- Data collection
- Where
- United States
- Volunteers
- 1,516 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection Leading to Cervical Cancer
A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.
The purpose of this study was to assess the safety and reactogenicity of GSK Biologicals' Cervarix vaccine in healthy female Filipino subjects from the age of 10 years onwards, as per the Bureau of Food and Drugs Directive of…
- Trial name
- NCT00730847
- Testing
- Cervarix
- Where
- 2 sites in Philippines
- Volunteers
- 743 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer
Cervical Cancer Elimination -Using Implementation Science to Evaluate Deliver and Cost Introduction of Thermal Ablation
Global elimination of cervical cancer is a feasible goal; however, the countries with the greatest disease burden also have the greatest healthcare system challenges.
- Trial name
- TIBA (NCT05472311)
- Testing
- Thermal Ablation
- Where
- Kenya
- Volunteers
- 565 people, healthy volunteers welcome
- Sponsor
- University of Washington
Human Papilloma Virus
A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls
Cervical cancer is the most common cancer in women aged 15-44 years in East Africa, and mortality rates are very high. HPV vaccines are most effective if given to girls who have not yet acquired HPV infection.
- Trial name
- DoRIS (NCT02834637)
- Testing
- bivalent HPV vaccine, nonavalent HPV vaccine
- Where
- Tanzania
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Patient With Invasive Cervical Carcinoma, Patient With CIN Lesion
Evaluation of ELISA Assay on Human Papilloma Viruses (HPV) Infection Population
Cervical cancer the most frequent neoplasm and the fifth mortality rate of malignancies of the women in the world. It results in about 1,000 women in Taiwan and about 200,000 women worldwide dying of cervical cancer each year.
- Conditions
- Patient With Invasive Cervical Carcinoma, Patient With CIN Lesion, Patient With HPV Infected Patients Without Histopathologic Lesion, Normal Populations.
- Trial name
- NCT00673192
- Testing
- peripheral blood isolation
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 008/580299 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00849381
- Testing
- GSK580299, GSK Biological's HPV vaccine
- Where
- 9 sites in Brazil, Taiwan and 1 more
- Volunteers
- 1,239 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Carcinoma, Human Papillomavirus Infection
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention.
- Trial name
- NCT06611540
- Testing
- Biospecimen Collection, Cervical Biopsy, Colposcopy
- Where
- 11 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
HPV Infection, HPV-Related Cervical Carcinoma
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
A total of 480 Chinese women aged 18-26 years old were enrolle，experimental group and the control group were randomly assigned in a ratio of 3:1. 360 Chinese women in the experimental group and 120 in the control group.
- Trial name
- NCT04436133
- Testing
- Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha), 9-valent HPV vaccine（Gardasil 9）
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China